1333.44.1 Boehringer Ingelheim Investigational Site
Ingelheim, Germany
NCT Number: NCT02225626
Effect of food on the pharmacokinetics of BI 1060469 (formulation tablet) in healthy male subjects as well as to investigate pharmacokinetics, safety and tolerability
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Phase 1
Ingelheim, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
Time frame: up to 6 days after last drug administration
Time frame: up to 6 days after last drug administration
Time frame: up to 7 days after last drug administration
Time frame: up to 6 days after last drug administration
Boehringer Ingelheim
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05207878
Healthy, Peripheral Nerve Injury Upper Limb
St Louis, Missouri, United States
View Trial DetailsNCT03876314
Alzheimer Disease, Behavior
Greensboro, North Carolina, United States
View Trial DetailsNCT07778186
Healthy, Nuclear Medicine Undergraduate Medical Education
Chengdu, Sichuan, China
View Trial DetailsNCT07778472
Healthy, Pathological Conditions, Signs and Symptoms
West Palm Beach, Florida, United States
View Trial Details